A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with T1D, and GLP-1 RA prescriptions also increased.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss Date: April 30, 2025 Start time: 12:30 ...

A cancer-causing protein long thought to be resistant to medication could soon be the target of new drugs, thanks to the work ...

During the time period 2020 to 2023, approximately 1 in 5 youth and 1 in 3 adults with type 1 diabetes and severe obesity ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

While medications like Ozempic and Wegovy are delivering positive weight loss outcomes, many consumers only use them for a relatively short period, giving better-for-you brands and retailers an ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...